Back to News
Market Impact: 0.28
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Source: 247wallst.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Moderna shares surged Monday after its Phase 3 adjuvant melanoma study of intismeran autogene was selected for a Presidential Symposium presentation. The selection highlights visibility for Moderna's investigational individualized mRNA neoantigen therapy, though the article provides no clinical-efficacy data or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
MRNA0.72
More News
- Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug
- Taiwan benchmark Taiex rises to record intraday high as tech stocks advance
- AMD joins the $1 trillion club as chip rally surges - our AI Strategy saw it early
- +17% in a single session: This AI-picked stock catches a data-center breakout
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club
- Intel surges 12% as CPU stocks rally. Here's what's driving the move